MHRA approves Valneva’s chikungunya vaccine Ixchiq for use in adults
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use in adults. Ixchiq is now the first vaccine approved in the UK to prevent disease caused by the chikungunya virus (CHIKV) in individuals aged 18 years and older.
Valneva’s chikungunya vaccine wins UK approval
Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), allowing the single-dose vaccine to be made available for adults. France-based Valneva has also submitted label extension applications in the US,
Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®
The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada 4 in adults 18 years of age and older.
UK MHRA grants marketing authorization to Valneva’s chikungunya vaccine, Ixchiq
UK MHRA grants marketing authorization to Valneva’s chikungunya vaccine, Ixchiq: Saint Herblain, France Thursday, February 6, 2025, 12:00 Hrs [IST] Valneva SE, a specialty vacci
Valneva receives authorisation for world’s first Chikungunya vaccine
Valneva has recieved Medicines and Healthcare products Regulatory Agency (MHRA) authorisation in the UK for the world’s first - and only - Chikungunya vaccine, IXCHIQ. The single-dose vaccine is indicated for active immunisation for the prevention of disease caused by Chikungunya virus (CHIKV) in individuals 18 years of age and older.
IXCHIQ Vaccine Approved for Chikungunya Protection
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 February 2025, approved the vaccine chikungunya vaccine (live) (brand name
MHRA grants Valneva marketing authorization for chikungunya vaccine
Valneva (VALN) announced that the Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization in the United
UK grants approval for Valneva’s chikungunya vaccine
French biotech Valneva has secured marketing approval in the UK for its chikungunya vaccine, Ixchiq (chikungunya vaccine), marking the fourth regulatory approval for the world’s first vaccine against the virus.
Valneva stock holds $18 target on UK vaccine nod
H.C. Wainwright reaffirmed its Buy rating and $18.00 price target for Valneva (EPA:VLS) SE (NASDAQ:VALN) shares, following the recent approval of the company's Ixchiq vaccine in the United Kingdom ...
Valneva Is A 'Buy' As A First-Mover In Chikungunya
Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...
pharmaphorum3d
CHMP backs Bavarian Nordic's chikungunya jab
Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...
Nasdaq15d
Valneva Advances IXCHIQ Chikungunya Vaccine To Phase 3 Trial In Children
(RTTNews) - Valneva SE (VALN) a specialty vaccine company, on Wednesday announced that it is advancing to a Phase 3 trial for IXCHIQ, its single-dose chikungunya vaccine, in children aged 1 to 11 ...
Hosted on MSN5d
EMA recommends Bavarian Nordic’s chikungunya vaccine for adults and teenagers
If authorised, Vimkunya would be the first vaccine in the EU to protect adolescents aged 12 to 17 against Chikungunya.